WILMINGTON, DE, and MONTREAL, QC, Jan. 30 /PRNewswire-FirstCall/ - Millenia Hope Inc., , is pleased to announce that, through Millenia Hope Biopharma (MH-B), it has finalized a contract with Sederma S.A.S. of France. Since 1964, Sederma has been devoted to the development of active ingredients and the creation of innovative concepts for the cosmetic industry. Conducting ongoing research and incorporating the latest scientific advancements into the products they bring to the market, Sederma has a stake in products that are plant derived.
MH-B is a world leader in Phytomics Technology and is ideally suited through its expertise, infrastructure, and library of phytochemicals to deliver on natural product discovery and development.
MH-B is extremely pleased to associate itself with a highly regarded international organization such as Sederma and looks forward to future collaborations.
ABOUT MILLENIA HOPE:
Millenia Hope develops innovative treatments and products that enhance the quality of life, has put in place programs to fight major infectious diseases, and promote healthier lives. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions.
ABOUT MILLENIA HOPE BIOPHARMA
Millenia Hope Biopharma (MH-B) is one of the world’s leading bioresearch firms in Phytomic Technologies, commercializing plant-cell based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. MH-B has spent over $30 million in developing its unique Phytomics Technologies, including the world’s largest library of highly purified phytochemical fractions to be utilized by the pharmaceutical, cosmetic and nutraceutical industry. MH-B is in the midst of the commercializing several projects with leading multi-national corporations.
SAFE HARBOR STATEMENTS:
Certain statements made in the release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Millenia Hope/Millenia Hope Biopharma that may be referred to as “forward-looking statements.” Several important factors could cause actual results to differ materially from those in such forward-looking statements and Millenia Hope could encounter unanticipated obstacles and delays in developing products, services, and markets.
MILLENIA HOPE BIOPHARMA
CONTACT: Dr. Bahige Baroudy, (514) 846-5757, (514) 288-8822,bahigebaroudy@milleniahope.com, www.milleniahope.com
